English	French	Notes	Complete/Exclude
25. GLEASON'S SCORE FOR BIOPSY, LOCAL RESECTION, OR SIMPLE PROSTATECTOMY			
26. GLEASON'S SCORE FOR RADICAL PROSTATECTOMY			
18. BEHAVIOR CODE (ICD-O-2)			
 10. CLASS OF CASE................: 			
 11. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:			
659     LOWER BACK PAIN..............			
660     TROUBLE URINATING............			
 12. INITIAL METHOD OF DIAGNOSIS:			
661     CLINICAL DX WITH BONE LESION.			
662     CLINICAL DX BY RECTAL EXAM...			
664     DIGITAL TRANSRECTAL BIOPSY...			
665     INCIDENTAL FINDING IN TURP                                                      FOR BENIGN DISEASE...........			
666     NEEDLE BIOPSY, NOS...........			
667     PERINEAL BIOPSY..............			
669     TRUS GUIDED BIOPSY...........			
 13. DIAGNOSTIC EVALUATION:			
671     BONE MARROW ASPIRATION.......			
672     BONE SCAN....................			
675     CT SCAN OF ABDOMEN...........			
676     CT SCAN OF PELVIS............			
679     PELVIC LYMPH NODE DISSECTION.			
683     ULTRASOUND OF ABDOMEN........			
684 14. RESULTS OF MOST RECENT PRE-                                                     TREATMENT PSA TEST...........			
 16. PRIMARY SITE (ICD-O-2).......: C61.9			
 18. BEHAVIOR CODE (ICD-O-2)......: 			
141 20. BIOSPY PROCEDURE.............			
 21. GUIDANCE OF BIOPSY TO PRIMARY: Not guided, no biopsy			
 22. BIOPSY APPROACH FOR PRIMARY..: No biopsy			
 21. GUIDANCE OF BIOPSY TO PRIMARY: Unknown/death cert only			
 22. BIOPSY APPROACH FOR PRIMARY..: Unknown/death cert only			
142 21. GUIDANCE OF BIOSPY TO PRIMARY			
145 22. BIOSPY APPROACH FOR PRIMARY..			
146 23. BIOSPY OF OTHER THAN PRIMARY.			
26 24. DIAGNOSTIC CONFIRMATION......			
 25. GLEASON'S SCORE FOR BIOPSY, LOCAL RESECTION, OR SIMPLE PROSTATECTOMY:			
     Surgery codes not 02 through 40			
     GLEASON SCORE................: 99 Unknown, not reported, or NA			
     GLEASON SCORE................: 			
623     GLEASON SCORE................			
 26. GLEASON'S SCORE FOR RADICAL PROSTATECTOMY:			
     Surgery codes not 50 through 70			
623.3     GLEASON SCORE................			
27. SIZE OF TUMOR (mm)			
28. REGIONAL NODES EXAMINED			
29. REGIONAL NODES POSITIVE			
30. AJCC CLINICAL STAGE (cTNM)			
31. AJCC PATHOLOGIC STAGE (pTNM)			
32. STAGED BY			
 TABLE III - EXTENT AND STAGE OF DISEASE			
29 27. SIZE OF TUMOR (mm).....			
33 28. REGIONAL NODES EXAMINED			
32 29. REGIONAL NODES POSITIVE			
 30. AJCC CLINICAL STAGE (cTNM):			
 31. AJCC PATHOLOGIC STAGE (pTNM):			
 32. STAGED BY:			
19     CLINICAL STAGE.........			
89     PATHOLOGIC STAGE.......			
 33. DATE OF FIRST COURSE TREATMENT.: 			
685 34. EXPECTED MGT/WATCHFUL WAITING..			
 35. DATE OF NON CA-DIRECTED SURGERY: 			
 36. NON CANCER-DIRECTED SURGERY....: 			
 37. DATE OF CANCER-DIRECTED SURGERY: 			
 38. LENGTH OF STAY AFTER SURGERY...: 88 NA			
 38. LENGTH OF STAY AFTER SURGERY...: 99 Unknown			
686 38. LENGTH OF STAY AFTER SURGERY...			
 39. SURGICAL APPROACH..............: 			
 40. TYPE OF CANCER-DIRECTED SURGERY: 			
 41. SURGICAL MARGINS...............: 			
 42. SCOPE OF LYMPH NODE SURGERY....: 			
 43. TYPE OF LYMPH NODE SURGERY:			
 44. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),			
     OR DISTANT LYMPH NODE(S).......: 			
 45. NUMBER OF LYMPH NODES REMOVED..: 			
 47. COMPLICATIONS FOLLOWING SURGICAL FIRST COURSE OF TREATMENT:			
     PERMANENT RECTAL INJURY........: NA, no surgery			
     THROMBOEMBOLISM................: NA, no surgery			
     URETHRAL STRICTURE.............: NA, no surgery			
 48. POSTOPERATIVE DEATH W/I 30 DAYS: NA, no surgery			
     PERMANENT RECTAL INJURY........: Unknown			
     URETHRAL STRICTURE.............: Unknown			
 48. POSTOPERATIVE DEATH W/I 30 DAYS: Unknown			
689     PERMANENT RECTAL INJURY........			
691     URETHRAL STRICTURE.............			
441 48. POSTOPERATIVE DEATH W/I 3O DAYS			
 49. DATE RADIATION STARTED.........: 			
 50. RADIATION THERAPY..............: 			
 51. RADIATION FACILITY.............: 			
 52. INTERSTITIAL RADIATION/BRACHYTHERAPY ADMINISTERED:			
     OTHER INTERSTITIAL, NOS........: 			
 53. ROUTE OF INTERSTITIAL RADIATION/			
     BRACHYTHERAPY ADMINISTERED.....: 			
 54. EXTERNAL RADIATION ADMINISTERED:			
     DISTANT METASTATIC SITES.......: 			
     PROSTATE & PELVIC NODES........: 			
     PROSTATE & PARA-AORTIC NODES...: 			
     PROSTATE REGION ONLY...........: 			
     OTHER EXTERNAL SITES, NOS......: 			
 55. TYPE OF EXTERNAL RADIATION			
 56. TOTAL EXTERNAL RAD DOSE (cGy) INCLUDING BOOST:			
     PELVIC NODES...................: 			
     PARA-AORTIC NODES..............: 			
 57. COMPLICATIONS FOLLOWING RADIATION FIRST COURSE OF TREATMENT:			
     ACUTE GASTROINTESTINAL.........: 			
     ACUTE GASTROURINARY............: 			
     CHRONIC REQUIRING SURGERY OR			
     PROLONGED HOSPITALIZATION......: 			
     URETHRAL OR BLADDER............: 			
692 51. RADIATION FACILITY.............			
631     OTHER INTERSTITIAL, NOS........			
693 53. ROUTE OF INTERSTITIAL RADIATION/                                                BRACHYTHERAPY ADMINISTERED.....			
636     DISTANT METASTATIC SITES.......			
634     PROSTATE & PELVIC NODES........			
635     PROSTATE & PARA-AORTIC NODES...			
633     PROSTATE REGION ONLY...........			
637     OTHER EXTERNAL SITES, NOS......			
694 55. TYPE OF EXTERNAL RADIATION                                                      ADMINISTRATION.................			
639     PELVIC NODES...................			
640     PARA-AORTIC NODES..............			
695     ACUTE GASTROINTESTINAL.........			
696     ACUTE GASTROURINARY............			
698     CHRONIC REQUIRING SURGERY OR                                                    PROLONGED HOSPITALIZATION......			
699     URETHRAL OR BLADDER............			
 58. DATE OF ORCHIECTOMY............: 00/00/0000			
699.1 58. DATE OF ORCHIECTOMY............			
 59. DATE EXOGENOUS HT BEGAN........: 			
 60. HORMONE THERAPY................: 			
 61. EXOGENOUS HORMONE AGENTS ADMINISTERED:			
     LUTEINIZING HORMONES...........: 			
     PROGESTATIONAL AGENTS..........: 			
646     LUTEINIZING HORMONES...........			
645     PROGESTATIONAL AGENTS..........			
 62. DATE CHEMOTHERAPY STARTED......: 			
64. DATE OF FIRST RECURRENCE			
65. TYPE OF FIRST RECURRENCE			
64. TYPE OF FIRST RECURRENCE			
65. DATE OF FIRST RECURRENCE			
70 64. DATE OF FIRST RECURRENCE			
71 65. TYPE OF FIRST RECURRENCE			
66. DATE OF LAST CONTACT OR DEATH			
67. VITAL STATUS			
68. CANCER STATUS			
69. COMPLETED BY			
70. CLINICAL REVIEW BY CA COMMITTEE			
 66. DATE OF LAST CONTACT OR DEATH..: 			
15 67. VITAL STATUS...................			
 68. CANCER STATUS..................: 			
81 69. COMPLETED BY...................			
82 70. CLINICAL REVIEW BY CA COMMITTEE			
 8. PRIMARY PAYER AT DIAGNOSIS.......: 			
 9. FAMILY HISTORY OF PROSTATE CANCER: 			
10. CLASS OF CASE....................: 			
11. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:			
     LOWER BACK PAIN.................: 			
     TROUBLE URINATING...............: 			
12. INITIAL METHODS OF DIAGNOSIS:			
     CLINICAL DX W BONE LESION.......: 			
     CLINICAL DX BY RECTAL EXAM......: 			
     DIGITAL TRANSRECTAL BIOPSY......: 			
     INCIDENTAL FINDING IN TURP FOR                                                  BENIGN DISEASE..................: 			
     NEEDLE BIOPSY, NOS..............: 			
     PERINEAL BIOPSY.................: 			
     TRUS GUIDED BIOPSY..............: 			
13. DIAGNOSTIC EVALUATION:			
     BONE MARROW ASPIRATION..........: 			
     BONE SCAN.......................: 			
     CT SCAN OF ABDOMEN..............: 			
     CT SCAN OF PELVIS...............: 			
     PELVIC LYMPH NODE DISSECTION....: 			
     ULTRASOUND OF ABDOMEN...........: 			
14. RESULTS OF MOST RECENT PRE-			
    TREATMENT PSA TEST...............: 			
15. DATE OF INITIAL DIAGNOSIS........: 			
16. PRIMARY SITE (ICD-O-2)...........: 			
18. BEHAVIOR CODE (ICD-O-2)..........: 			
20. BIOPSY PROCEDURE.................: 			
21. GUIDANCE OF BIOPSY TO PRIMARY....: 			
22. BIOPSY APPROACH FOR PRIMARY......: 			
23. BIOPSY OF OTHER THAN PRIMARY.....: 			
24. DIAGNOSTIC CONFIRMATION..........: 			
     GLEASON SCORE...................: 			
27. SIZE OF TUMOR (mm)...............: 			
28. REGIONAL NODES EXAMINED..........: 			
29. REGIONAL NODES POSITIVE..........: 			
30. AJCC CLINICAL STAGE (cTNM):			
31. AJCC PATHOLOGIC STAGE (pTNM):			
32. STAGED BY:			
33. DATE OF FIRST COURSE TREATMENT...: 			
34. EXPECTED MGT/WATCHFUL WAITING....: 			
35. DATE OF NON CA-DIRECTED SURGERY..: 			
36. NON CANCER-DIRECTED SURGERY......: 			
37. DATE OF CANCER-DIRECTED SURGERY..: 			
38. LENGTH OF STAY AFTER SURGERY.....: 			
39. SURGICAL APPROACH................: 			
40. TYPE OF CANCER-DIRECTED SURGERY..: 			
41. SURGICAL MARGINS.................: 			
42. SCOPE OF LYMPH NODE SURGERY......: 			
43. TYPE OF LYMPH NODE SURGERY:			
44. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),			
45. NUMBER OF LYMPH NODES REMOVED....: 			
47. COMPLICATIONS FOLLOWING SURGICAL FIRST COURSE OF TREATMENT:			
     PERMANENT RECTAL INJURY.........: 			
     URETHRAL STRICTURE..............: 			
48. POSTOPERATIVE DEATH W/I 30 DAYS..: 			
49. DATE RADIATION STARTED...........: 			
50. RADIATION THERAPY................: 			
51. RADIATION FACILITY...............: 			
52. INTERSTITIAL RADIATION/BRACHYTHERAPY ADMINISTERED:			
     OTHER INTERSTITIAL, NOS.........: 			
53. ROUTE OF INTERSTITIAL RADIATION/			
    BRACHYTHERAPY ADMINISTERED.......: 			
54. EXTERNAL RADIATION ADMINISTERED:			
     DISTANT METASTATIC SITES........: 			
     PROSTATE & PELVIC NODES.........: 			
     PROSTATE & PARA-AORTIC NODES....: 			
     PROSTATE REGION ONLY............: 			
     OTHER EXTERNAL SITES, NOS.......: 			
55. TYPE OF EXTERNAL RADIATION			
56. TOTAL EXTERNAL RAD DOSE (cGy) INCLUDING BOOST:			
     PELVIC NODES....................: 			
     PARA-AORTIC NODES...............: 			
57. COMPLICATIONS FOLLOWING RADIATION FIRST COURSE OF TREATMENT:			
     ACUTE GASTROINTESTINAL..........: 			
     ACUTE GASTROURINARY.............: 			
     PROLONGED HOSPITALIZATION.......: 			
     URETHRAL OR BLADDER.............: 			
58. DATE OF ORCHIECTOMY.............: 			
59. DATE EXOGENOUS HT BEGAN.........: 			
60. HORMONE THERAPY.................: 			
61. EXOGENOUS HORMONE AGENTS ADMINISTERED:			
     LUTEINIZING HORMONES............: 			
     PROGESTATIONAL AGENTS...........: 			
62. DATE CHEMOTHERAPY STARTED........: 			
64. DATE OF FIRST RECURRENCE.........: 			
65. TYPE OF FIRST RECURRENCE.........: 			
66. DATE OF LAST CONTACT OR DEATH....: 			
67. VITAL STATUS.....................: 			
68. CANCER STATUS....................: 			
69. COMPLETED BY.....................: 			
70. REVIEWED BY CANCER COMMITTEE.....: 			
ROADS TO FORDS			
7    PLACE OF BIRTH.............			
9    SPANISH ORIGIN.............//^S X=			
Non-Spanish, non-Hispanic			
48    AGENT ORANGE EXPOSURE......//^S X=AOE			
50    IONIZING RADIATION EXPOSURE//^S X=IRE			
52    CHEMICAL EXPOSURE..........			
61    ASBESTOS EXPOSURE..........			
51    PERSIAN GULF SERVICE.......//^S X=PGS			
55    MIDDLE EAST SERVICE........//^S X=MES			
56    SOMALIA SERVICE............//^S X=SS			
 Reporting Hospital..........: 			
 Marital status at Dx........: 			
 Patient address at Dx.......: 			
 Patient address at Dx - Supp: 			
 City/town at Dx.............: 			
 State at Dx.................: 			
 Postal code at Dx...........: 			
 County at Dx................: 			
 Census Tract................: 			
 Following physician.........: 			
 Primary surgeon.............: 			
 Primary payer at Dx.........: 			
 Type of reporting source....: 			
 Class of Case................: 			
 Facility referred from.......: 			
 Facility referred to.........: 			
 Date of First Contact........: 			
 Date Dx......................: 			
 Dx Facility..................: 			
 Histology/Behavior Code......: 			
 AFIP submission..............: 			
 Diagnostic Confirmation......: 			
 Presentation at Cancer Conf..: 			
    Place of birth.............: 			
    Spanish origin.............: 			
    Agent Orange exposure......: 			
    Ionizing radiation exposure: 			
    Chemical exposure..........: 			
    Asbestos exposure..........: 			
    Persian Gulf service.......: 			
    Middle East service........: 			
    Somalia service............: 			
    Usual Occupation...........: 			
    Usual Industry.............: 			
    Tobacco History............: 			
    Alcohol History............: 			
    Family History of Cancer...: 			
    Family Member with Cancer..: 			
 PREVIOUS HISTORY OF CANCER			
 Previous History of Cancer.....: 			
1///Unknown if BRM therapy administered			
Patient Care Evaluation Studies of Cancer of the Prostate			
DATE OF ADMISSION			
ACCESSION/SEQUENCE NUMBER.: 			
CLASS OF CASE.............: 			
9ZIP CODE..................			
BIRTHDATE.................: 			
18PRIMARY PAYER AT DIAGNOSIS			
1DATE OF ADMISSION.........			
1.1DATE OF DISCHARGE.........			
METHOD OF DIAGNOSIS			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################